Miromatrix Medical Inc. (MIRO)
Dec 13, 2023 - MIRO was delisted (reason: acquired by United Therapeutics)
3.390
0.00 (0.00%)
Last trade price
Miromatrix Medical Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Miromatrix Medical stock has a target of 3.00, which predicts a decrease of -11.50% from the current stock price of 3.39.
Analyst Consensus: Buy
* Price targets were last updated on May 12, 2023.
Analyst Ratings
According to 1 stock analyst, the rating for MIRO is "Buy". This means that the analyst believes this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '23 | Sep '23 | Oct '23 | Nov '23 | Dec '23 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $6 → $3 | Buy | Maintains | $6 → $3 | -11.50% | May 12, 2023 |
| Piper Sandler | Piper Sandler | Buy Maintains $9 → $6 | Buy | Maintains | $9 → $6 | +76.99% | Apr 3, 2023 |
| Piper Sandler | Piper Sandler | Buy Maintains $8 → $9 | Buy | Maintains | $8 → $9 | +165.49% | Nov 15, 2022 |
| Piper Sandler | Piper Sandler | Buy Initiates $8 | Buy | Initiates | $8 | +135.99% | Aug 31, 2022 |
Financial Forecast
Revenue This Year
14.28K
from 953.47K
Decreased by -98.50%
Revenue Next Year
13.77K
from 14.28K
Decreased by -3.57%
EPS This Year
-0.98
from -1.45
EPS Next Year
-0.87
from -0.98
Revenue Forecast
| Revenue | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| High | 29,400 | 28,350 | 28,350 | 25.2M | 113.4M |
| Avg | 14,280 | 13,770 | 13,770 | 24.5M | 110.2M |
| Low | n/a | n/a | n/a | 23.5M | 105.9M |
Revenue Growth
| Revenue Growth | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| High | -96.9% | 98.5% | 105.9% | 183,109.9% | 362.8% |
| Avg | -98.5% | -3.6% | - | 177,881.1% | 349.6% |
| Low | - | - | - | 170,894.9% | 332.0% |
EPS Forecast
| EPS | 2023 | 2024 | 2025 |
|---|---|---|---|
| High | -0.93 | -0.86 | -1.12 |
| Avg | -0.98 | -0.87 | -1.10 |
| Low | -1.01 | -0.86 | -1.06 |
EPS Growth
| EPS Growth | 2023 | 2024 | 2025 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.